ABOLERIS PHARMA
THE IMMUNE SYSTEM UNDER CONTROL

AbolerIS Pharma's co-founder Dr. Carole Guillonneau receives Albert Sezary Prize from the National Academy of Medicine.

December 15th, 2020,

AbolerIS Pharma, a biotechnology company developing innovative immunotherapies, today announces that Carole Guillonneau, Ph.D., director of research CNRS and co-founder of AbolerIS Pharma, has received the 2020 Albert Sezary Prize from the National Academy of Science. Dr. Guillonneau was honored for her work in the field of tolerance and her leadership role in the development of new immunotherapy to the clinic performed at the Center of Research in Transplantation and Immunology (CRTI) in France.

The Albert Sezary Prize intend to reward each year in France a young researcher worthy of interest. The prize is awarded by the French National Academy of Medicine, a scientific center of excellence created in 1820 by king Louis XVIII which contributes to medical research through bequests and donations.

Dr. Guillonneau completed her PhD at the University of Paris VII in 2005. She then joined for a post-doctorate in 2006, thanks to a prestigious European Marie Curie fellowship, the laboratory of Professor Peter Doherty, Nobel Prize winner in medicine, in Melbourne, Australia. In 2009, she was recruited as a researcher at the CNRS and joined the CRTI in Nantes. Since 2017, she is co-leading team 2 "Genetic and cellular engineering in tolerance and regenerative medicine" and is more particularly interested in understanding the mechanisms of tolerance and the generation of new therapeutic strategies through the study of a population of regulatory T cells known as $CD8^+$ Treg. Her work has been recognized by several licensed patents and the creation of AbolerIS Pharma, a start-up spin-off of CRTI. Her goals are now to transfer her results to the clinic.

AbolerIS Pharma's lead program is a first in class anti-CD45RC antibody to target pathogenic T cells involved in tissue-destructive immune responses in acute graft-vs.-host disease, rejection of transplanted organs, autoimmune diseases and immune-mediated inflammatory diseases. This treatment promotes immune tolerance through development of antigen-specific regulatory T cells.

About AbolerIS Pharma. (http://aboleris-pharma.com/). AbolerIS Pharma is a recently created biotechnology company that develops new immunotherapies in the field of autoimmune diseases, immune-mediated inflammatory diseases and transplantation. The company develops several molecules, such as the anti-CD45RC monoclonal antibody. Together with the optimization of its molecules, research and development are key focus areas of AbolerIS Pharma activity. AbolerIS Pharma recently obtained seed investment of 2.5 M€ from Newton Biocapital and Turenne Santé/Sham Innovation Santé (http://aboleris-pharma.com/wp-content/uploads/2020/11/press-release-seed-AbolerIS-Pharma-Vf.pdf)

About CRTI –http://www.itun.nantes.inserm.fr/. The CRTI is a joint research unit (UMR 1064) created by INSERM and Université de Nantes. The CRTI is located at the Nantes University Hospital where it constitutes with several clinical departments the Institute of Transplantation Urology and Nephrology. The CRTI is part of the Labex Immunology Graft Oncology, a regional cluster of immunology laboratories and of the Nantes cluster of research (SFR). This unique environment fosters interactions between basic scientists and clinicians, supported by the most updated technological platforms and explains the strong commitment of the CRTI to translational research. The main and long-term objectives of CRTI are to improve treatments and patient monitoring in transplantation and immune-mediated inflammatory diseases through understanding immune responses, developing new immunotherapeutics, biomarkers and tools for personalized medicine and developing alternative strategies for organ or tissue replacement.

For further information please contact:
Ann Meulemans (PhD), CEO
AbolerIS Pharma
e-mail : ann.meulemans@aboleris-pharma.com